Synta CMO resigns

A day after GlaxoSmithKline reported that it was dumping its collaboration with Synta Pharmaceuticals for elesclomol, Synta Chief Medical Officer Eric W. Jacobson, M.D., a senior vice president, announced his resignation.

WuXi PharmaTech announced that Felix Hsu has been appointed senior vice president of WuXi AppTec U.S.

Cadence Pharmaceuticals has named Scott Byrd as the company's senior vice president and chief commercial officer.

Hemispherx Biopharma announced the appointment of Robert Dickey IV as senior vice president.

Transition Therapeutics named Laura Agensky as vice-president of clinical operations.

Genocea Biosciences announced that Robert Farrell Jr., CPA has joined the company as vice president, finance and administration.

Calcionics Corporation named Daniel Wilds executive chairman of the company's board of directors.

MacroGenics announced today that Paulo Costa has been elected to the company's board as an independent director.

Cancer Therapeutics, an emerging biotechnology business incubator, named R. Paul Gray to its advisory board.


Avid Radiopharmaceuticals announced that founder and CEO Daniel Skovronsky, M.D., Ph.D., received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category in Greater Philadelphia.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.